Cargando…

Biomarkers for Predicting Clinical Outcomes of Chemoradiation-Based Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer

Chemoradiation-based bladder preservation therapy (BPT) is currently a curative option for non-metastatic muscle-invasive bladder cancer (MIBC) patients at favorable risk or an alternative to radical cystectomy (RC) for those who are unfit for RC. In BPT, only patients who achieve complete response...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koga, Fumitaka, Takemura, Kosuke, Fukushima, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165010/ https://www.ncbi.nlm.nih.gov/pubmed/30223570 http://dx.doi.org/10.3390/ijms19092777

Ejemplares similares

Impact of sarcopenia in bladder preservation therapy for muscle-invasive bladder cancer patients: a narrative review
por: Fukushima, Hiroshi, et al.
Publicado: (2022)

Will chemoradiation-based bladder-sparing therapy become a standard of care for muscle-invasive bladder cancer?
por: Koga, Fumitaka
Publicado: (2020)

Impact of Sarcopenia as a Prognostic Biomarker of Bladder Cancer
por: Fukushima, Hiroshi, et al.
Publicado: (2018)

Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer
por: Elsayed, Dalia Hamouda, et al.
Publicado: (2023)

Allelic imbalance at 1p36 may predict prognosis of chemoradiation therapy for bladder preservation in patients with invasive bladder cancer
por: Matsumoto, H, et al.
Publicado: (2004)

Bladder Preservation with Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for the Treatment of Muscle-invasive Carcinoma of the Bladder: A Single-Center Experience
por: Agrawal, Chinmayee, et al.
Publicado: (2020)

Bladder Preservation for Muscle Invasive Bladder Cancer
por: Mirza, Arafat, et al.
Publicado: (2016)

Outcomes by time to definitive chemoradiation treatment for patients with muscle-invasive bladder cancer
por: Kotha, Nikhil V., et al.
Publicado: (2022)

Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer
por: Rose, Tracy L., et al.
Publicado: (2016)

ErbB2 and NFκB Overexpression as Predictors of Chemoradiation Resistance and Putative Targets to Overcome Resistance in Muscle-Invasive Bladder Cancer
por: Koga, Fumitaka, et al.
Publicado: (2011)

Treatment Discontinuation in Patients With Muscle-Invasive Bladder Cancer Undergoing Chemoradiation
por: Kotha, Nikhil V., et al.
Publicado: (2021)

The Effect of Tri-Modality Therapy with Bladder Preservation for Selective Muscle-Invasive Bladder Cancer
por: Zhiyu, Zhang, et al.
Publicado: (2021)

Where are we with bladder preservation for muscle-invasive bladder cancer in 2017?
por: Smelser, Woodson Wade, et al.
Publicado: (2017)

Bladder preservation in muscle-invasive bladder cancer: a comprehensive review
por: Hamad, Judy, et al.
Publicado: (2020)

Endoclips as novel fiducial markers in trimodality bladder-preserving therapy of muscle-invasive bladder carcinoma: feasibility and patient outcomes
por: Shahbaz, Muhammad, et al.
Publicado: (2020)

Trimodality Therapy in which Concurrent Chemoradiation with Concomitant Boost in Muscle Invasive TCC Urinary Bladder Cancer
por: Mohammed, Ayatallah Ali Youssief, et al.
Publicado: (2023)

High-grade hyperinvasive sarcomatoid urothelial bladder carcinoma demonstrating complete response to bladder-preserving chemoradiation
por: Wallach, J.B., et al.
Publicado: (2009)

Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder
por: Michaelson, M D, et al.
Publicado: (2004)

Trimodality Therapy for Bladder Preservation in the Elderly Population with Invasive Bladder Cancer
por: Turgeon, Guy-Anne, et al.
Publicado: (2014)

Outcome following radical cystectomy and bladder-preservation therapy in patients with invasive carcinoma of urinary bladder
por: Yadav, B. S., et al.
Publicado: (2008)

Elevated Baseline Neutrophil Count Correlates with Worse Outcomes in Patients with Muscle-Invasive Bladder Cancer Treated with Chemoradiation
por: Meunier, Sébastien, et al.
Publicado: (2023)

The updated outcomes of bladder-preserving trimodal therapy using a real-time tumor-tracking radiotherapy system for patients with muscle-invasive bladder cancer
por: Miyata, Haruka, et al.
Publicado: (2020)

Single Institutional Experience of Bladder-Preserving Trimodality Treatment for Muscle-Invasive Bladder Cancer
por: Joung, Jae Young, et al.
Publicado: (2008)

Editorial comment: bladder preservation as a treatment strategy in muscle-invasive bladder cancer
por: Ajib, Khaled, et al.
Publicado: (2018)

Comparison of sequential versus concurrent chemoradiation regimens in non-metastatic muscle-invasive bladder cancer
por: Vieira, Heidi M., et al.
Publicado: (2023)

Editorial Comment: Endoclips as novel fiducial markers in trimodality bladder preserving therapy of muscle-invasive bladder carcinoma: feasibility and patient outcomes
por: dos Reis, Rodolfo Borges, et al.
Publicado: (2020)

Tumor Markers as Predictors of Acute Kidney Injury Incidence and Staging of the Muscle-Invasive Bladder Cancer Receiving Chemoradiation Therapy
por: Warli, Syah Mirsya, et al.
Publicado: (2023)

A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer
por: Portner, R., et al.
Publicado: (2021)

The Significance of Neutrophil-to-Lymphocyte Ratio and Combined Chemoradiotherapy in Patients Undergoing Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer
por: Wu, Chun-Te, et al.
Publicado: (2020)

Nuclear Factor-κB Overexpression is Correlated with Poor Outcomes after Multimodality Bladder-Preserving Therapy in Patients with Muscle-Invasive Bladder Cancer
por: Chiang, Yun, et al.
Publicado: (2019)

Ultrasound-Mediated Gemcitabine Delivery Reduces the Normal-Tissue Toxicity of Chemoradiation Therapy in a Muscle-Invasive Bladder Cancer Model
por: Ruan, Jia-Ling, et al.
Publicado: (2021)

Bladder preservation in non-metastatic muscle-invasive bladder cancer (MIBC): a single-institution experience
por: Gerardi, Marianna A., et al.
Publicado: (2016)

Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial Outcomes
por: Garcia, Maurice M., et al.
Publicado: (2014)

Transurethral resection of bladder tumor-based bladder preservation therapy for refractory high risk non-muscle invasive bladder cancer: Current landscape and future directions
por: Sun, Xinghui, et al.
Publicado: (2023)

Metabolomics of Non-muscle Invasive Bladder Cancer: Biomarkers for Early Detection of Bladder Cancer
por: Cheng, Xiangming, et al.
Publicado: (2018)

Bladder preservation with brachytherapy compared to cystectomy for T1-T3 muscle-invasive bladder cancer: a systematic review
por: Bos, Manouk K., et al.
Publicado: (2014)

Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
por: Sung, Hyun Hwan, et al.
Publicado: (2022)

Correction: Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial Outcomes
por: Garcia, Maurice M., et al.
Publicado: (2016)

Predictive molecular biomarkers for determining neoadjuvant chemosensitivity in muscle invasive bladder cancer
por: Murphy, Neal, et al.
Publicado: (2022)

Perioperative therapy in muscle invasive bladder cancer
por: Chatterjee, Ambarish, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kjqmtgpb5ej7a9u7j10t62bfb3